Joseph Beaulieu Biography and Net Worth

Insider of Epizyme


Joseph Beaulieu is the Controller, Treasurer & Principal Accounting Officer at Epizyme Inc.

What is Joseph Beaulieu's net worth?

The estimated net worth of Joseph Beaulieu is at least $7,577.85 as of June 26th, 2020. Mr. Beaulieu owns 5,155 shares of Epizyme stock worth more than $7,578 as of April 25th. This net worth estimate does not reflect any other assets that Mr. Beaulieu may own. Learn More about Joseph Beaulieu's net worth.

How old is Joseph Beaulieu?

Mr. Beaulieu is currently 41 years old. There are 5 older executives and no younger executives at Epizyme. The oldest executive at Epizyme is Mr. Grant C. Bogle, Pres, CEO, Principal Financial Officer & Director, who is 64 years old. Learn More on Joseph Beaulieu's age.

How do I contact Joseph Beaulieu?

The corporate mailing address for Mr. Beaulieu and other Epizyme executives is 400 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. Epizyme can also be reached via phone at (617) 229-5872 and via email at [email protected]. Learn More on Joseph Beaulieu's contact information.

Has Joseph Beaulieu been buying or selling shares of Epizyme?

Joseph Beaulieu has not been actively trading shares of Epizyme over the course of the past ninety days. Most recently, Joseph Beaulieu sold 222 shares of the business's stock in a transaction on Monday, February 7th. The shares were sold at an average price of $1.50, for a transaction totalling $333.00. Learn More on Joseph Beaulieu's trading history.

Who are Epizyme's active insiders?

Epizyme's insider roster includes Shefali Agarwal (Insider), Robert Bazemore Jr. (CEO), Joseph Beaulieu (Insider), Jeffery Kutok (Insider), Pablo Legorreta (Director), and David Mott (Director). Learn More on Epizyme's active insiders.

Joseph Beaulieu Insider Trading History at Epizyme

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/7/2022Sell222$1.50$333.00View SEC Filing Icon  
9/3/2020Sell971$12.77$12,399.67View SEC Filing Icon  
6/26/2020Sell317$16.15$5,119.555,155View SEC Filing Icon  
3/25/2020Sell212$15.28$3,239.365,173View SEC Filing Icon  
3/3/2020Sell996$22.18$22,091.28View SEC Filing Icon  
See Full Table

Joseph Beaulieu Buying and Selling Activity at Epizyme

This chart shows Joseph Beaulieu's buying and selling at Epizyme by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Epizyme Company Overview

Epizyme logo
Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $1.47
Low: $1.47
High: $1.47

50 Day Range

MA: $1.47
Low: $1.47
High: $1.52

2 Week Range

Now: $1.47
Low: $0.41
High: $5.80

Volume

7,960 shs

Average Volume

3,225,203 shs

Market Capitalization

$247.44 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A